tiprankstipranks
DENTSPLY SIRONA Inc (XRAY)
NASDAQ:XRAY
US Market
XRAY
DENTSPLY SIRONA
RESEARCH TOOLSreports
Want to see XRAY full AI Analyst Report?

DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target

574 Followers
See the Price Targets and Ratings of:

XRAY Analyst Ratings

Hold
13Ratings
Hold
3 Buy
8 Hold
2 Sell
Based on 13 analysts giving stock ratings to
DENTSPLY
SIRONA
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

XRAY Stock 12 Month Forecast

Average Price Target

$14.27
▲(14.09% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for DENTSPLY SIRONA in the last 3 months. The average price target is $14.27 with a high forecast of $18.00 and a low forecast of $10.00. The average price target represents a 14.09% change from the last price of $12.51.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","14":"$14","19":"$19","11.5":"$11.5","16.5":"$16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.272727272727272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,11.5,14,16.5,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.66,12.147692307692308,12.635384615384616,13.123076923076923,13.61076923076923,14.098461538461539,14.586153846153847,15.073846153846155,15.561538461538461,16.049230769230768,16.536923076923078,17.024615384615384,17.512307692307694,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.66,11.860979020979022,12.061958041958041,12.262937062937063,12.463916083916084,12.664895104895106,12.865874125874125,13.066853146853147,13.267832167832168,13.468811188811188,13.669790209790209,13.87076923076923,14.07174825174825,{"y":14.272727272727272,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.66,11.532307692307693,11.404615384615385,11.276923076923078,11.149230769230769,11.021538461538462,10.893846153846154,10.766153846153847,10.638461538461538,10.510769230769231,10.383076923076922,10.255384615384616,10.127692307692307,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.111,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.418,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.046,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.093,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.913,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.913,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.765,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.43,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.21,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.31,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$18.00Average Price Target$14.27Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on XRAY
Daniel Grosslight
Citi
Citi
$10
Sell
-20.06%
Downside
Initiated
04/16/26
Dentsply Sirona initiated with a Sell at CitiDentsply Sirona initiated with a Sell at Citi
Evercore ISI Analyst forecast on XRAY
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$15→$13
Hold
3.92%
Upside
Reiterated
04/08/26
Dentsply Sirona price target lowered to $13 from $15 at Evercore ISIDentsply Sirona price target lowered to $13 from $15 at Evercore ISI
Barclays Analyst forecast on XRAY
Glen Santangelo
Barclays
Barclays
$12
Sell
-4.08%
Downside
Reiterated
03/30/26
Barclays Remains a Sell on DENTSPLY SIRONA (XRAY)
Needham Analyst forecast on XRAY
David Saxon
Needham
Needham
―
Hold
―
Reiterated
03/16/26
Reaffirming Hold: Updated Earnings Outlook and Interest Assumptions Support Fair Valuation
UBS Analyst forecast on XRAY
Kevin Caliendo
UBS
UBS
$16→$18
Buy
43.88%
Upside
Reiterated
03/02/26
Dentsply Sirona price target raised to $18 from $16 at UBSDentsply Sirona price target raised to $18 from $16 at UBS
Barrington Analyst forecast on XRAY
Michael Petusky
Barrington
Barrington
$14→$17
Buy
35.89%
Upside
Reiterated
03/02/26
Dentsply Sirona price target raised to $17 from $14 at BarringtonDentsply Sirona price target raised to $17 from $14 at Barrington
Mizuho Securities Analyst forecast on XRAY
Steven Valiquette
Mizuho Securities
Mizuho Securities
$14→$16
Hold
27.90%
Upside
Reiterated
03/02/26
Dentsply Sirona price target raised to $16 from $14 at MizuhoDentsply Sirona price target raised to $16 from $14 at Mizuho
Wells Fargo Analyst forecast on XRAY
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$13
Hold
3.92%
Upside
Reiterated
02/27/26
Wells Fargo Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
Robert W. Baird Analyst forecast on XRAY
Jeff Johnson
Robert W. Baird
Robert W. Baird
$12→$14
Hold
11.91%
Upside
Reiterated
02/27/26
Dentsply Sirona price target raised to $14 from $12 at BairdDentsply Sirona price target raised to $14 from $12 at Baird
Stifel Nicolaus Analyst forecast on XRAY
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$13→$14
Hold
11.91%
Upside
Reiterated
02/27/26
Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (NASDAQ: ARQT), DENTSPLY SIRONA (NASDAQ: XRAY) and Edgewise Therapeutics (NASDAQ: EWTX)
William Blair Analyst forecast on XRAY
Brandon Vazquez
William Blair
William Blair
―
Hold
―
Reiterated
02/27/26
Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Solventum Corporation (NYSE: SOLV) and Privia Health Group (NASDAQ: PRVA)
Piper Sandler Analyst forecast on XRAY
Jason Bednar
Piper Sandler
Piper Sandler
$13
Hold
3.92%
Upside
Reiterated
02/27/26
Piper Sandler Sticks to Their Hold Rating for DENTSPLY SIRONA (XRAY)
Bank of America Securities Analyst forecast on XRAY
Allen Lutz
Bank of America Securities
Bank of America Securities
$13→$17
Buy
35.89%
Upside
Upgraded
02/19/26
Dentsply Sirona upgraded to Buy from Neutral at BofADentsply Sirona upgraded to Buy from Neutral at BofA
J.P. Morgan Analyst forecast on XRAY
Lilia-Celine (Lily) Lozada
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
12/19/25
Analysts Offer Insights on Healthcare Companies: Novavax (NASDAQ: NVAX) and DENTSPLY SIRONA (NASDAQ: XRAY)
Morgan Stanley Analyst forecast on XRAY
Erin Wright
Morgan Stanley
Morgan Stanley
$14→$12
Hold
-4.08%
Downside
Reiterated
11/07/25
Dentsply Sirona price target lowered to $12 from $14 at Morgan StanleyDentsply Sirona price target lowered to $12 from $14 at Morgan Stanley
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on XRAY
Daniel Grosslight
Citi
Citi
$10
Sell
-20.06%
Downside
Initiated
04/16/26
Dentsply Sirona initiated with a Sell at CitiDentsply Sirona initiated with a Sell at Citi
Evercore ISI Analyst forecast on XRAY
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$15→$13
Hold
3.92%
Upside
Reiterated
04/08/26
Dentsply Sirona price target lowered to $13 from $15 at Evercore ISIDentsply Sirona price target lowered to $13 from $15 at Evercore ISI
Barclays Analyst forecast on XRAY
Glen Santangelo
Barclays
Barclays
$12
Sell
-4.08%
Downside
Reiterated
03/30/26
Barclays Remains a Sell on DENTSPLY SIRONA (XRAY)
Needham Analyst forecast on XRAY
David Saxon
Needham
Needham
―
Hold
―
Reiterated
03/16/26
Reaffirming Hold: Updated Earnings Outlook and Interest Assumptions Support Fair Valuation
UBS Analyst forecast on XRAY
Kevin Caliendo
UBS
UBS
$16→$18
Buy
43.88%
Upside
Reiterated
03/02/26
Dentsply Sirona price target raised to $18 from $16 at UBSDentsply Sirona price target raised to $18 from $16 at UBS
Barrington Analyst forecast on XRAY
Michael Petusky
Barrington
Barrington
$14→$17
Buy
35.89%
Upside
Reiterated
03/02/26
Dentsply Sirona price target raised to $17 from $14 at BarringtonDentsply Sirona price target raised to $17 from $14 at Barrington
Mizuho Securities Analyst forecast on XRAY
Steven Valiquette
Mizuho Securities
Mizuho Securities
$14→$16
Hold
27.90%
Upside
Reiterated
03/02/26
Dentsply Sirona price target raised to $16 from $14 at MizuhoDentsply Sirona price target raised to $16 from $14 at Mizuho
Wells Fargo Analyst forecast on XRAY
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$13
Hold
3.92%
Upside
Reiterated
02/27/26
Wells Fargo Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
Robert W. Baird Analyst forecast on XRAY
Jeff Johnson
Robert W. Baird
Robert W. Baird
$12→$14
Hold
11.91%
Upside
Reiterated
02/27/26
Dentsply Sirona price target raised to $14 from $12 at BairdDentsply Sirona price target raised to $14 from $12 at Baird
Stifel Nicolaus Analyst forecast on XRAY
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$13→$14
Hold
11.91%
Upside
Reiterated
02/27/26
Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (NASDAQ: ARQT), DENTSPLY SIRONA (NASDAQ: XRAY) and Edgewise Therapeutics (NASDAQ: EWTX)
William Blair Analyst forecast on XRAY
Brandon Vazquez
William Blair
William Blair
―
Hold
―
Reiterated
02/27/26
Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Solventum Corporation (NYSE: SOLV) and Privia Health Group (NASDAQ: PRVA)
Piper Sandler Analyst forecast on XRAY
Jason Bednar
Piper Sandler
Piper Sandler
$13
Hold
3.92%
Upside
Reiterated
02/27/26
Piper Sandler Sticks to Their Hold Rating for DENTSPLY SIRONA (XRAY)
Bank of America Securities Analyst forecast on XRAY
Allen Lutz
Bank of America Securities
Bank of America Securities
$13→$17
Buy
35.89%
Upside
Upgraded
02/19/26
Dentsply Sirona upgraded to Buy from Neutral at BofADentsply Sirona upgraded to Buy from Neutral at BofA
J.P. Morgan Analyst forecast on XRAY
Lilia-Celine (Lily) Lozada
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
12/19/25
Analysts Offer Insights on Healthcare Companies: Novavax (NASDAQ: NVAX) and DENTSPLY SIRONA (NASDAQ: XRAY)
Morgan Stanley Analyst forecast on XRAY
Erin Wright
Morgan Stanley
Morgan Stanley
$14→$12
Hold
-4.08%
Downside
Reiterated
11/07/25
Dentsply Sirona price target lowered to $12 from $14 at Morgan StanleyDentsply Sirona price target lowered to $12 from $14 at Morgan Stanley
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering DENTSPLY SIRONA

3 Months
xxx
Success Rate
12/37 ratings generated profit
32%
Average Return
-5.22%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 32.43% of your transactions generating a profit, with an average return of -5.22% per trade.
1 Year
Michael PetuskyBarrington
Success Rate
6/37 ratings generated profit
16%
Average Return
-22.19%
Copying Michael Petusky's trades and holding each position for 1 Year would result in 16.22% of your transactions generating a profit, with an average return of -22.19% per trade.
2 Years
xxx
Success Rate
3/37 ratings generated profit
8%
Average Return
-34.56%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 8.11% of your transactions generating a profit, with an average return of -34.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XRAY Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
2
1
0
0
0
Buy
3
3
4
5
4
Hold
15
16
14
14
10
Sell
1
1
2
2
3
Strong Sell
0
0
0
0
0
total
21
21
20
21
17
In the current month, XRAY has received 4 Buy Ratings, 10 Hold Ratings, and 3 Sell Ratings. XRAY average Analyst price target in the past 3 months is 14.27.
Each month's total comprises the sum of three months' worth of ratings.

XRAY Financial Forecast

XRAY Earnings Forecast

Next quarter’s earnings estimate for XRAY is $0.28 with a range of $0.22 to $0.40. The previous quarter’s EPS was $0.27. XRAY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year XRAY has Performed in-line its overall industry.
Next quarter’s earnings estimate for XRAY is $0.28 with a range of $0.22 to $0.40. The previous quarter’s EPS was $0.27. XRAY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year XRAY has Performed in-line its overall industry.

XRAY Sales Forecast

Next quarter’s sales forecast for XRAY is $841.77M with a range of $815.00M to $872.00M. The previous quarter’s sales results were $961.00M. XRAY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year XRAY has Performed in-line its overall industry.
Next quarter’s sales forecast for XRAY is $841.77M with a range of $815.00M to $872.00M. The previous quarter’s sales results were $961.00M. XRAY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year XRAY has Performed in-line its overall industry.

XRAY Stock Forecast FAQ

What is XRAY’s average 12-month price target, according to analysts?
Based on analyst ratings, DENTSPLY SIRONA Inc’s 12-month average price target is 14.27.
    What is XRAY’s upside potential, based on the analysts’ average price target?
    DENTSPLY SIRONA Inc has 14.09% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is XRAY a Buy, Sell or Hold?
          DENTSPLY SIRONA Inc has a consensus rating of Hold which is based on 3 buy ratings, 8 hold ratings and 2 sell ratings.
            What is DENTSPLY SIRONA Inc’s price target?
            The average price target for DENTSPLY SIRONA Inc is 14.27. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $18.00 ,the lowest forecast is $10.00. The average price target represents 14.09% Increase from the current price of $12.51.
              What do analysts say about DENTSPLY SIRONA Inc?
              DENTSPLY SIRONA Inc’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of XRAY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.